Durham, N.C. (February 26, 2008) – Expression Analysis, Inc., the industry’s leading provider of genomic services for clinical trails and research, announced today that it has initiated service for Illumina’s Assays for DNA Methylation profiling. The assays are highly reproducible and multiplexed methods for the high-throughput quantitative measurement of DNA methylation.
“Most microarray based DNA methylation analysis platforms are limited in their specimen throughput capacity, and generally require relatively large amounts of high-quality input DNA,” explained Dr. Tom Goralski, Senior Director of Laboratory Operations at Express Analysis. “Illumina’s platform supports a high sample throughput, and also greatly expands the number of CpG islands that can be simultaneously interrogated. This technology will drastically increase the scope and speed of our clients’ methylation research and biomarker discovery studies,” concluded Goralski.
Expression Analysis now offers both Illumina’s GoldenGate Assay and an Infinium based Assay for DNA Methylation. The GoldenGate Assay can test up to 1,536 client specified CpG islands per assay and a pre-designed Cancer Panel assay incorporating 1,505 CpG islands is also available. The Infinium Assay incorporates 27,000 CpG islands. DNA isolation services are available form the company.
About Expression Analysis, Inc. Expression Analysis, Inc. provides expression profiling and genotyping and sequencing services using Illumina BeadChip®, Affymetrix GeneChip® and Applied Biosystems’ TaqMan technologies. As the leading provider of microarray services in clinical trails and research, Expression Analysis offers solutions for challenging specimens such as blood and FFPE tissues, as well as nucleic acid isolation and data analysis services. The organizations CLIA registered lab supports GLP compliance.
